Bibliografia

  1. Vaede D, Warnet JM, Brignole-Baudouin F .Preervatives in eye drops: toward awareness of their toxicity. J Fr Ophtalmol.2010 Sep:33(7)
  2. E,Warcoin,C.Clouzeau, F. Brignol-Baudouin, C. Baudouin. Hiperosmolarité: effets intracellulairs et implications dans la checeresse oculair. Journal Français d Ophtalmologie (2016),39,641-645.
  3. Eamon W. Leung. MD, Felipe A. Medeiros MD, PhD, and Robert N. Weinreb, MD. Prevalence of Ocular Surface Disease in Glaucoma Patients . J Glaucoma. Volume17,Number 5,August 2008 :350-355.
  4. DEWS report; The Ocular Surface . April 2007, vol 5 nº 2
  5. Ivan Goldberg, Franzco Fracs, Colin I. Clement,MBBS,PhD,Tina H. Chiang,Pharm D, John G. Walt, MBA, Lauren J. Lee, Pharm D Stuart Graham. Assessing Quality of Life in Patients With Glaucoma Using the Glaucoma Quality of Life-15 (GQL-15) Questionnaire. J Glaucoma;vol18;nº1;january 2009:6-12
  6. Georgios Labiris et al. Vision-specific Quality of Life in Greek Glaucoma Patients. J Glaucoma;vol 19;n1; January 2010:39-43.
  7. C. Van Went et al. Évaluation de la sensibilité cornéenne chez les patients traités médicalement pour un glaucome ou une hipertonie oculaire. Journal français d’ophtalmologie ;2011; 34:684-690
  8. De Saint Jean M. Debbasch C., Brignole F. et al. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro modelo f conjuntival cells. Curr Eye Res. 2000;20: 85-94.
  9. Guenoun JM. Baudouin C.Rat P. et al. In vitro study of inflamatory potential of Latanoprost, Travoprost and Bimatoprost in conjuntival-derived epitelial cells. Invest Ophthalmol Vis Sci. 2005: 46:2444-2450.
  10. Jo Ellen Stryker,Phd, Allen Dale Beck,MD Susan A. Primo, OD, MPH, Katharina V. Echt, PhD, Lucja Bundy EdM, Grace Cho Pretorius,MPH and Karen Glanz, PhD,MPH. An Exploratory Study of Glaucoma Adherence. J. Glaucoma. Vol 19, Number 1, January 2010: 66-72.
  11. C. Van Went, E. Brasnu, P. Hamard, C. Baudouin, A.Labbé. Influence des pathologies de la surface oculaire sur le traitement du glaucome. In Journal Français d’Ophtalmologie; Avril 2011; vol34:230-23
  12. Makoto Aihara, Md, Phd, Shin-Ichiro Otani, MD, Jun Kosaki, MD, Kazuhiko Unoki, MD, Masamitsu Takeuchi, PhD, Kazunori Miyata, MD, PhD. Long-term Effect of BAK –free Travoprost on Ocular Surface and Intraocular Pressure in Glaucoma Patients After Transition From Latanoprost. J Glaucoma.vol 21, Number 1 January 2012;60-64.
  13. Brignole-Badouin et al. Travatan Bak-free in vitro. In “Glaucoma & Ocular Surface Health, a slide resource”, an Alcon Cornea & Glaucoma Summit. 2011
  14. Liang H et al. Travatan Baak free solution in vivo . In “Glaucoma & Ocular Surface Health, a slide resource”, an Alcon Cornea & Glaucoma Summit. 20111
4ª Edição - Maio 2017